Skip to main navigation Skip to search Skip to main content

An orally bioavailable SARS-CoV-2 main protease inhibitor exhibits improved affinity and reduced sensitivity to mutations

  • Michael Westberg
  • , Yichi Su
  • , Xinzhi Zou
  • , Pinghan Huang
  • , Arjun Rustagi
  • , Jaishree Garhyan
  • , Puja Bhavesh Patel
  • , Daniel Fernandez
  • , Yan Wu
  • , Chenzhou Hao
  • , Chieh Wen Lo
  • , Marwah Karim
  • , Lin Ning
  • , Aimee Beck
  • , Panatda Saenkham-Huntsinger
  • , Vivian Tat
  • , Aleksandra Drelich
  • , Bi Hung Peng
  • , Shirit Einav
  • , Chien Te K. Tseng
    • Catherine Blish, Michael Z. Lin

Research output: Contribution to journal › Article › peer-review

32   Link opens in a new tab Scopus citations

Fingerprint

Dive into the research topics of 'An orally bioavailable SARS-CoV-2 main protease inhibitor exhibits improved affinity and reduced sensitivity to mutations'. Together they form a unique fingerprint.
Sort by

Pharmacology, Toxicology and Pharmaceutical Science

Keyphrases